Cisplatinum

cis-Diamminedichloroplatinum(II); cis-DDP; CDDP; cis-[Pt(NH3)2Cl2] · Cisplatin; Cisplatinum; Platinol; Platamine; cis-platinum

Modern MM

A modern drug-based remedy with NO formal proving. Its theoretical sphere of action is read directly from cisplatin's documented organ toxicology: the gastrointestinal tract (intractable nausea/vomiting), kidneys and electrolyte balance, the auditory nerve (tinnitus, hearing loss), peripheral sensory nerves, and bone marrow. Any clinical use is by analogy under the Law of Similars and is not supported by pathogenetic trial data.

Key symptoms

No keynotes exist from a homeopathic proving. The only verifiable symptom-image is the toxicological one: violent, persistent nausea and vomiting (cisplatin is among the most emetogenic of all chemotherapeutic agents); cumulative kidney injury with magnesium/potassium/calcium wasting; ototoxicity — tinnitus and high-frequency, often irreversible hearing loss; peripheral sensory neuropathy with numbness and tingling of the extremities; and bone-marrow suppression. These are pharmacological/toxicological effects, NOT proving symptoms, and must not be presented as classical keynotes.

Worse (aggravation)

Not established. No proving exists, so no validated modalities of aggravation can be stated.

Better (amelioration)

Not established. No proving exists, so no validated modalities of amelioration can be stated.

Manohar V Nagaiah

Materia Medica of Modern Homeopathic Medicine · 2026

Cisplatin; Cisplatinum; Platinol; Platamine; cis-platinum

Source & Nature

CISPLATINUM is the homeopathic name for the platinum chemotherapy drug cisplatin, cis-diamminedichloroplatinum(II) — formula Cl2H6N2Pt (cis-[Pt(NH3)2Cl2]), molecular weight 300.05 g/mol, CAS 15663-27-1, PubChem CID 5460033. It is a square-planar platinum(II) coordination complex and a first-generation platinum-based antineoplastic agent.

First described by Michele Peyrone in 1845, its anticancer activity was discovered by Barnett Rosenberg in the 1960s and it entered oncology practice for testicular cancer in 1974 (FDA approval December 1978). It remains a cornerstone agent for testicular, ovarian, bladder, cervical, head-and-neck, esophageal and lung cancers.

Continue Modern MM in the app

Classical texts are in the public domain. Educational reference only — not medical advice.